How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Female Infertility Diagnosis and Treatment Market
- By Diagnosis Method: Hormonal Testing, Ultrasound Imaging, Hysterosalpingography (HSG), Laparoscopy, Ovarian Reserve Testing
- By Treatment Type: Ovulation Induction Therapy, Intrauterine Insemination (IUI), In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), Surgical Treatment for Endometriosis, Tubal Surgery
- By Cause of Infertility: Ovulatory Disorders, Tubal Factor Infertility, Endometriosis, Uterine Factor Infertility, Unexplained Infertility
- By End User: Fertility Clinics, Hospitals, Diagnostic Laboratories, Specialized Reproductive Centers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Hormonal Testing leads By Diagnosis Method at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.169 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.177 →
Full report · locked preview
Everything inside the Female Infertility Diagnosis and Treatment Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Diagnosis Method 5
Treatment Type 6
Cause of Infertility 5
End User 4
Companies profiled
CooperSurgical Inc.
Ferring Pharmaceuticals
Merck KGaA (Merck Serono)
Thermo Fisher Scientific
GE Healthcare
Hologic Inc.
Sartorius AG
Vitrolife AB
Cook Medical
Progyny Inc.
IVF-Life
Genea Biomedx
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →CooperSurgical Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Ferring Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Merck KGaA (Merck Serono)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →GE Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Hologic Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Sartorius AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Vitrolife AB
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Cook Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Progyny Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →IVF-Life
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Genea Biomedx
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →ReproMed
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →OvaScience (now part of OvaScience
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →a subsidiary of Millendo Therapeutics)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Invitro
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,728M by 2033 · 11.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Hormonal Testing38.3
- Ultrasound Imaging17.3
- Hysterosalpingography (HSG)15.0
- Laparoscopy15.9
- Ovarian Reserve Testing13.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$382.8M → $954.9M · 12.1%
Europe$266.8M → $647.8M · 11.7%
Asia Pacific$243.6M → $529.8M · 10.2%
Latin America$150.8M → $368.0M · 11.8%
Middle East and Africa$116.0M → $249.8M · 10.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.242026
11.242027
11.262028
11.262029
11.292030
11.292031
11.302032
11.322033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- CooperSurgical Inc.15.5
- Ferring Pharmaceuticals15.5
- Merck KGaA (Merck Serono)12.0
- Thermo Fisher Scientific10.2
- GE Healthcare5.4
- Hologic Inc.13.4
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Diagnosis Method26.4%
Treatment Type23.9%
Cause of Infertility22.9%
End User26.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.7
- Europe23.6
- Asia Pacific19.3
- Latin America13.4
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| CooperSurgical Inc. | 94 | 90 | 82 | 88 | 86 | 84 | 87 |
| Ferring Pharmaceuticals | 70 | 84 | 69 | 93 | 88 | 83 | 81 |
| Merck KGaA (Merck Serono) | 66 | 87 | 82 | 81 | 66 | 79 | 77 |
| Thermo Fisher Scientific | 65 | 73 | 58 | 76 | 76 | 65 | 69 |
| GE Healthcare | 77 | 61 | 75 | 60 | 73 | 60 | 68 |
| Hologic Inc. | 51 | 52 | 47 | 52 | 46 | 68 | 53 |
| Sartorius AG | 55 | 44 | 59 | 41 | 58 | 44 | 50 |
| Vitrolife AB | 51 | 48 | 46 | 40 | 45 | 42 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- CooperSurgical Inc.
- Ferring Pharmaceuticals
- Merck KGaA (Merck Serono)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| CooperSurgical Inc. | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Ferring Pharmaceuticals | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Merck KGaA (Merck Serono) | ◐ | ✓ | ◐ | ✓ | − | ✓ |
| Thermo Fisher Scientific | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| GE Healthcare | ◐ | − | − | ◐ | ✓ | − |
| Hologic Inc. | ◐ | ◐ | − | − | − | ◐ |
| Sartorius AG | ◐ | ◐ | ◐ | − | − | − |
| Vitrolife AB | − | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1CooperSurgical Inc.87
2Ferring Pharmaceuticals81
3Merck KGaA (Merck Serono)77
4Thermo Fisher Scientific69
5GE Healthcare68
6Hologic Inc.53
7Sartorius AG50
8Vitrolife AB45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
CooperSurgical Inc.Ferring Pharmaceuticals
Challenger3
Strong scale, closing on the leaders.
Merck KGaA (Merck Serono)Thermo Fisher ScientificGE Healthcare
Niche3
Specialists in a single segment or region.
Hologic Inc.Sartorius AGVitrolife AB
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Diagnosis Method in North America, then scale across Female Infertility Diagnosis and Treatment Market — a $467M beachhead inside a $7.81B market.
Beachhead (SOM)$467Mobtainable near-term
Serviceable (SAM)$3.25Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Hormonal Testing
Best fit — highest urgency & budget in Diagnosis Method.
Economic buyer79 fit
Ultrasound Imaging
Strong fit — clear ROI and a fast path to value.
End user69 fit
Hysterosalpingography (HSG)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Diagnosis Method in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Cause of Infertility
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve18%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Diagnosis Method leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Female Infertility Diagnosis and Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified26%
Evaluation13%
Closed-won5%
$12.6KCAC
$46KLTV
3.6:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Female Infertility Diagnosis and Treatment Market is a durable-growth opportunity — $8.31B by 2033, compounding at 8.5%.
TAM · 2025$4.32Btoday
TAM · 2033$8.31Bforecast
CAGR8.5%2027–2033
Cumulative$55.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.31BTotal addressable market
SAM$3.03BServiceable available market
SOM$597MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.5% CAGR
Demand compounds through 2033, outpacing GDP across Diagnosis Method.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Diagnosis Method moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.31BLarge & growingTAM by 2033 at 8.5% CAGR
$3.03BServiceable nowreachable with today’s model
$597MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.48BBear5.6% CAGR
$8.31BBase8.5% CAGR
$10.6BBull11.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Female Infertility Diagnosis and Treatment Market — a $5.52B market by 2033. Plan: grow share from 6.2% to 11.0%.
Market size · 2033$5.52Btotal addressable
Market CAGR4.5%2027–2033
Target share11.0%from 6.2% today
Revenue ambition$607Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.2% | 11.0% | Ahead |
| Revenue | $352M | $607M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 36.5% | 42.5% | Behind |
| Customer retention | 90.2% | 96.4% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Diagnosis Method
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Type capability
A defensible second engine — invest in Treatment Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Diagnosis Method share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $85M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Type
- Authorise North America expansion plan
- Fund R&D program for Diagnosis Method leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Female Infertility Diagnosis and Treatment Market conversation — a $6.12B market you can size, segment and defend in minutes.
Market size · 2033$6.12Btotal opportunity
Growth8.8%CAGR to 2033
Addressable buyers1,654+accounts in scope
Typical ROI7.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Diagnosis Method
Goal Grow share in Diagnosis Method
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.2×return on cost, year one
< 2 mopayback period
$95K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
CooperSurgical Inc.Ferring PharmaceuticalsMerck KGaA (Merck Serono)Thermo Fisher ScientificGE HealthcareHologic Inc.Sartorius AGVitrolife AB+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Female Infertility Diagnosis and Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Female Infertility Diagnosis and Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Inflammatory Heart Disease Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportIn-Vitro Diagnostic Market
Market size, share, segmentation and regional forecast.
$660M market · 2025 base year
View reportKidney Cancer Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportLung Cancer Diagnosis and Therapeutics Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportMale Infertility Diagnosis and Treatment Market
Market size, share, segmentation and regional forecast.
$560M market · 2025 base year
View reportMedia, Sera and Reagent Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportMedical Adhesives Therapeutics Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportInfrared Forehead Thermometers Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportMelanoma Cancer Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportOropharyngeal Cancer Diagnosis and Therapeutics Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportInfrared Flow Cytometry Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportPET-CT Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.